Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

GlaxoSmithKline (GSK - Analyst Report) and partner Theravance, Inc. (THRX - Analyst Report) received a boost with the U.S. Food and Drug Administration (FDA) approving Anoro Ellipta. The FDA cleared Anoro Ellipta (once daily) as a long-term maintenance therapy for airflow obstruction in patients suffering from chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema.

Anoro Ellipta is a combination of a long-acting muscarinic antagonist/LAMA (GSK573719 or umeclidinium bromide/UMEC) and a long-acting beta2 agonist/LABA (vilanterol/VI).

The U.S. approval of Anoro Ellipta was not surprising considering that the Pulmonary-Allergy Drugs Advisory Committee recommended the approval of the drug in Sep 2013. The approval triggers a milestone payment of $30 million from Theravance to Glaxo. Glaxo will receive a further payment of $30 million following the product launch. The launch activities related to Anoro Ellipta are expected to start from the first quarter of 2014.

We remind investors that in Oct 2013 Glaxo and Theravance had launched another COPD drug, Breo Ellipta, in the U.S.

Anoro Ellipta and Breo Ellipta, if successfully commercialized, will compensate for the loss of revenues once Advair – one of Glaxo’s highest revenue grossers – goes generic. The product generated sales of $3.9 billion in the first nine months of 2013, accounting for almost 25% of the company’s Pharmaceuticals and Vaccines segment revenues.

Both Glaxo and Theravance carry a Zacks Rank #3 (Hold). Some better-ranked stocks include Jazz Pharmaceuticals (JAZZ - Analyst Report) and Actelion Ltd. (ALIOF). Both companies hold a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVESTMENT T ITG 19.16 +3.34%
VERTEX ENERG VTNR 7.38 +3.07%